AIM1 dysregulation, through mislocalization and dissociation from the actin cytoskeleton, or AIM1 reduced expression and genomic loss, was common in prostate cancer and was associated with more aggressive, recurrent, or metastatic disease. This evidence concerns the gene CRYBG1 and prostate cancer.